BIOTYPE Launches MODAPLEX Molecular Diagnostics Platform

Dresden, Germany-based BIOTYPE has launched its MODAPLEX diagnostic platform for the fully integrated analysis for the detection and quantification of cancer-related RNA and DNA biomarkers, enabling professional laboratories to perform highly specialized molecular analyses quickly (in less than four hours) and easily in an automated manner (simultaneous measurement of decision-relevant RNA and DNA biomarkers from a single sample).

The MODAPLEX platform is an open system solution that enables third parties such as molecular testing system manufacturers or pharmaceutical companies, to develop and market their own assays, broadening the market of available tests and increasing the attractiveness of MODAPLEX for users who wish to obtain their test kits from multiple sources.

The launch of the next-generation MODAPLEX system also marks our entry into the international business for molecular testing platforms. In addition to molecular tests for highly specialised diagnostics of complex diseases, we are now expanding our portfolio to include software and instruments,” said Dr Norman Gerstner, CEO of BIOTYPE GmbH.

en_GBEnglish (UK)